LYRA - Lyra Therapeutics Inc logo

LYRA

Lyra Therapeutics Inc

Rev —top 1%5Y
Hold

Lyra Therapeutics develops anti-inflammatory therapies specifically for chronic rhinosinusitis. Its lead products include LYR-210, an implantable drug matrix in Phase III trials, and LYR-220 for patients needing ongoing CRS treatment.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $1today

Score Overview

1 Year
Score
Net Growth69.05%
Net TrendGrew
Net Income Consistency
Rev Growth-74.05%
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-30.70%
Net Trend20%
Net Income Consistency
Rev Growth
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-30.70%
Net Trend20%
Net Income Consistency
Rev Growth
Rev Trend60%
Revenue Consistency

See the full market ranking →

Lyra Therapeutics Inc fundamental performance

Across Lyra Therapeutics Inc's full reported history, from 2020 to 2025, revenue grew from $ 0.00 to $ 398K and net income went from -$ 22M to -$ 28M. Revenue increased in 60% of the years measured; net income in 20%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.25
1 Year2025-08-12
$ 6.75-96.30%
5 Years2021-08-12
$ 369.00-99.93%
All Time2020-05-01
$ 928.00-99.97%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 398K-$ 28M$ 15M
2024$ 1M-$ 93M$ 40M
2023$ 1M-$ 62M$ 102M
2022$ 1M-$ 55M$ 97M
2021$ 285K-$ 42M$ 45M
IPO2020$ 0.00-$ 22M$ 74M

Explore beyond LYRA

You're looking at Lyra Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies